Figure 1
Survival of patients aged 60 years or older with AML: comparison of treatment with GO vs no postremission treatment. Shown are overall survival (left) and disease-free survival (right). Patients in CR were randomized to 3 cycles of GO at 6 mg/m2 at 4-week intervals or no therapy. No indicates no postremission treatment.
